RxDoctor Payments Data

Amparo Gutierrez, MD

Neuromuscular Medicine · Orlando, FLNPI 1225051170

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $557,270 of the $809,809 with a category attached, or 68.8%. 60 manufacturers reported payments, led by EMD Serono, Inc. at 33.4% of the total.

$809,809in general payments, 2019–2025

Across 1,927 payments — averaging $420.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$271K
  • Biogen$226K
  • Sanofi$77K
  • TG Therapeutics, Inc.$59K
  • Novartis$52K
  • E.r. Squibb & Sons, L.L.C.$29K
  • plus $98K from 54 others
$3,759,319in research payments, 2019–2025

Across 92 payments — averaging $40,862 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$3.2M
  • Sanofi$346K
  • Biogen$102K
  • EMD Serono, Inc.$77K
  • TG Therapeutics, Inc.$20K
  • Sanofi US Services Inc.$237
  • plus $77 from 1 others

What the payments were for

  • Consulting fees$157,13419%
  • Speaking & faculty fees$557,27069%
  • Travel & lodging$42,2085%
  • Food & beverage$51,4606%
  • Education$8270%
  • Gifts$9110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.285$270,563
Biogen308$225,619
Sanofi143$76,964
TG Therapeutics, Inc.80$58,574
Novartis286$51,946
E.r. Squibb & Sons, L.L.C.27$28,588
Ares Trading SA5$21,393
Amgen(2 entities)78$19,770
Genentech USA, Inc.157$15,815
Johnson & Johnson(2 entities)31$12,425
AbbVie(2 entities)85$10,621
Bristol Myers Squibb89$3,974
AstraZeneca(2 entities)65$2,708
Banner Life Sciences, LLC27$1,795
Janssen Scientific Affairs, LLC2$1,760
Argenx US, Inc.18$1,083
Pfizer23$753
ANI Pharmaceuticals, Inc.7$513
Teva Pharmaceuticals USA, Inc.31$368
Genentech, Inc.4$345
Tanabe Pharma America, Inc.17$307
Biohaven Pharmaceuticals, Inc.9$275
Catalyst Pharmaceuticals, Inc.6$246
UCB, Inc.10$230
Neurelis, Inc.8$218
Grifols USA, LLC5$212
Acadia Pharmaceuticals Inc10$210
Amylyx Pharmaceuticals, Inc.4$182
Sanofi-aventis U.S. LLC4$169
Vanda Pharmaceuticals Inc.15$162
Otsuka America Pharmaceutical, Inc.8$157
EDW Pharma, Inc.2$145
Eisai Inc.2$139
Axsome Therapeutics, Inc.6$123
Lundbeck LLC5$121
Lilly USA, LLC8$120
Takeda Pharmaceuticals U.S.A., Inc.4$110
Mallinckrodt Hospital Products Inc.3$99
CSL Behring4$95
Mallinckrodt Enterprises LLC5$92
Biohaven Pharmaceutical Holding Company Ltd.4$89
Acorda Therapeutics, Inc4$76
Scilex Pharmaceuticals Inc.4$70
Xeris Pharmaceuticals, Inc.3$67
SK Life Science, Inc.3$64
Neurocrine Biosciences, Inc.2$50
Avanir Pharmaceuticals, Inc.3$48
Coloplast1$48
Mylan Specialty L.p.2$42
Alnylam Pharmaceuticals Inc.1$29
Strongbridge US Inc.2$29
Cycle Pharmaceuticals Inc2$28
Merz Pharmaceuticals, LLC1$25
GE HealthCare1$21
Livanova USA, Inc.1$20
Sumitomo Pharma America, Inc.1$20
ITF Therapeutics LLC1$19
Amneal Pharmaceuticals LLC1$17
Idorsia Pharmaceuticals US Inc1$17
Bayer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$68,722
Medicare patients
196
Services billed
3,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MavencladCladribine29$2,361,913
VumerityDiroximel Fumarate104$884,255
Kesimpta PenOfatumumab97$835,393
TecfideraDimethyl Fumarate17$258,329
Avonex (4 Pack)Interferon Beta-1a13$108,003
Dalfampridine ErDalfampridine141$95,501
NuedextaDextromethorphan Hbr/Quinidine24$40,596
QuliptaAtogepant31$32,805
MyrbetriqMirabegron30$25,940
UbrelvyUbrogepant19$22,729
Aimovig AutoinjectorErenumab-Aooe17$13,694
Emgality PenGalcanezumab-Gnlm12$11,363
Gabapentin438$8,234
Modafinil84$7,603
Baclofen332$7,425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Mavenclad$270,563$2,361,91329 claims
BiogenVumerity, Tecfidera, Avonex (4 Pack)$225,619$1,250,587134 claims
AbbVieQulipta, Ubrelvy$10,621$55,53450 claims
Avanir Pharmaceuticals, Inc.Nuedexta$48$40,59624 claims
PfizerDilantin$753$1,11312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →